IV 수액 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 영양소별, 최종 용도별, 지역별, 부문별 예측(2025-2033년)

Intravenous Solutions Market Summary

The global intravenous solutions market size was valued at USD 12.80 billion in 2024 and is expected to reach USD 28.2 billion by 2033, growing at a CAGR of 9.4% from 2025 to 2033. This growth is attributed to the increasing prevalence of diseases, such as neurological diseases, gastrointestinal diseases, and cancer.

IV solutions provide essential nutrients and are a main source of energy. The rising rates of premature births in developed countries such as the U.S. and the UK are further fueling the demand for intravenous (IV) solutions, as these nations have advanced neonatal care infrastructure that relies heavily on IV therapy. In these countries, factors such as increasing maternal age, higher rates of assisted reproductive technologies (ART), and chronic maternal conditions such as diabetes and hypertension have contributed to a growing number of preterm deliveries. For instance, according to Tommy's, the premature birth rate in England and Wales rose to 7.9% in 2022, up from 7.5% in 2021, marking two consecutive years of increase. Over 53,000 babies were born prematurely in 2022.

Malnutrition is one of the major drivers of the Intravenous (IV) solution market. According to the WHO, in 2022, 2.5 billion adults were overweight, with 890 million living with obesity, while 390 million were underweight. Globally, 149 million children under 5 were stunted, 45 million were wasted, and 37 million were overweight or obese. This high prevalence of malnutrition globally contributes to market growth. According to UNICEF, poor nutrition in the first 1,000 days of an infant's life may lead to impaired cognitive ability and stunted growth. Starch, minerals, vitamins, amino acids, lipids, and other key substances must be present in an infant's diet. These essential nutrients can be administered through parenteral nutrition, which is expected to boost the market. A high number of malnourished children and premature neonates that require these nutrients is expected to further propel the market.

Global Intravenous Solutions Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global intravenous solutions market report based on type, nutrient, end use and regions:

• Type Outlook (Revenue, USD Million, 2021 - 2033)
• Total Parenteral Nutrition
• Peripheral Parenteral Nutrition
• Nutrients Outlook (Revenue, USD Million, 2021 - 2033)
• Carbohydrates
• Vitamins & Minerals
• Single-dose Amino Acids
• Parenteral Lipid Emulsion
• Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Home
• Hospitals
• Infusion Centers
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Nutrient
  • 1.2.3. End use
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Growing Number of Premature Births
    • 3.2.1.2. Increasing Incidence of Cancer
    • 3.2.1.3. Increasing Risk of Malnutrition
    • 3.2.1.4. Growing Geriatric Population
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Shortage of Parenteral Nutrition Products
    • 3.2.2.2. Increased Use of Enteral Nutrition
    • 3.2.2.3. High Risk of Infections
  • 3.2.3. Industry Opportunity Analysis
  • 3.2.4. Industry Challenge Analysis
  • 3.2.5. Regulatory Framework
    • 3.2.5.1. Standards and Compliances
      • 3.2.5.1.1. North America
      • 3.2.5.1.2. Europe
      • 3.2.5.1.3. Asia Pacific
      • 3.2.5.1.4. Latin America
      • 3.2.5.1.5. MEA
• 3.3. Business Environment Analysis
  • 3.3.1. Porter's Five Forces Analysis
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTLE Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic and Social landscape
    • 3.3.2.3. Technological landscape
    • 3.3.2.4. Environmental landscape
    • 3.3.2.5. Legal Landscape

Chapter 4. Intravenous Solutions Market: Type Estimates & Trend Analysis

• 4.1. Type Segment Dashboard
• 4.2. Type Market Share Movement Analysis, 2024 & 2033
• 4.3. Market Size & Forecasts and Trend Analysis, by Type, 2021 to 2033 (Revenue USD Million)
• 4.4. Total Parenteral Nutrition
  • 4.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (Revenue USD Million)
• 4.5. Peripheral Parenteral Nutrition
  • 4.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (Revenue USD Million)

Chapter 5. Intravenous Solutions Market: Nutrient Estimates & Trend Analysis

• 5.1. Nutrient Segment Dashboard
• 5.2. Nutrient Market Share Movement Analysis, 2024 & 2033
• 5.3. Market Size & Forecasts and Trend Analysis, by Nutrient, 2021 to 2033 (Revenue USD Million)
• 5.4. Carbohydrates
  • 5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (Revenue USD Million)
• 5.5. Vitamins & Minerals
  • 5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (Revenue USD Million)
• 5.6. Single-dose Amino Acids
  • 5.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (Revenue USD Million)
• 5.7. Parenteral Lipid Emulsion
  • 5.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (Revenue USD Million)
• 5.8. Others
  • 5.8.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (Revenue USD Million)

Chapter 6. Intravenous Solutions Market: End Use Estimates & Trend Analysis

• 6.1. End use Segment Dashboard
• 6.2. End use Market Share Movement Analysis, 2024 & 2033
• 6.3. Market Size & Forecasts and Trend Analysis, by End Use, 2021 to 2033 (Revenue USD Million)
• 6.4. Home
  • 6.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (Revenue USD Million)
• 6.5. Hospitals
  • 6.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (Revenue USD Million)
• 6.6. Infusion Centers
  • 6.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (Revenue USD Million)

Chapter 7. Intravenous Solutions Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Dashboard
• 7.2. Regional Market: Key Takeaways
• 7.3. North America
  • 7.3.1. North America Intravenous Solutions market estimates and forecasts, 2021 - 2033 (Revenue USD Million)
  • 7.3.2. U.S.
    • 7.3.2.1. Key country dynamic
    • 7.3.2.2. Regulatory framework
    • 7.3.2.3. Competitive insights
    • 7.3.2.4. U.S. Intravenous Solutions market estimates and forecasts, 2021 - 2033 (Revenue USD Million)
  • 7.3.3. Canada
    • 7.3.3.1. Key country dynamic
    • 7.3.3.2. Regulatory framework
    • 7.3.3.3. Competitive insights
    • 7.3.3.4. Canada Intravenous Solutions market estimates and forecasts, 2021 - 2033 (Revenue USD Million)
  • 7.3.4. Mexico
    • 7.3.4.1. Key country dynamic
    • 7.3.4.2. Regulatory framework
    • 7.3.4.3. Competitive insights
    • 7.3.4.4. Mexico Intravenous Solutions market estimates and forecasts, 2021 - 2033 (Revenue USD Million)
• 7.4. Europe
  • 7.4.1. Europe Intravenous Solutions market estimates and forecasts, 2021 - 2033 (Revenue USD Million)
  • 7.4.2. Germany
    • 7.4.2.1. Key country dynamic
    • 7.4.2.2. Regulatory framework
    • 7.4.2.3. Competitive insights
    • 7.4.2.4. Germany Intravenous Solutions market estimates and forecasts, 2021 - 2033 (Revenue USD Million)
  • 7.4.3. UK
    • 7.4.3.1. Key country dynamic
    • 7.4.3.2. Regulatory framework
    • 7.4.3.3. Competitive insights
    • 7.4.3.4. UK Intravenous Solutions market estimates and forecasts, 2021 - 2033 (Revenue USD Million)
  • 7.4.4. France
    • 7.4.4.1. Key country dynamic
    • 7.4.4.2. Regulatory framework
    • 7.4.4.3. Competitive insights
    • 7.4.4.4. France Intravenous Solutions market estimates and forecasts, 2021 - 2033 (Revenue USD Million)
  • 7.4.5. Italy
    • 7.4.5.1. Key country dynamic
    • 7.4.5.2. Regulatory framework
    • 7.4.5.3. Competitive insights
    • 7.4.5.4. Italy Intravenous Solutions market estimates and forecasts, 2021 - 2033 (Revenue USD Million)
  • 7.4.6. Spain
    • 7.4.6.1. Key country dynamic
    • 7.4.6.2. Regulatory framework
    • 7.4.6.3. Competitive insights
    • 7.4.6.4. Spain Intravenous Solutions market estimates and forecasts, 2021 - 2033 (Revenue USD Million)
  • 7.4.7. Denmark
    • 7.4.7.1. Key country dynamic
    • 7.4.7.2. Regulatory framework
    • 7.4.7.3. Competitive insights
    • 7.4.7.4. Denmark Intravenous Solutions market estimates and forecasts, 2021 - 2033 (Revenue USD Million)
  • 7.4.8. Sweden
    • 7.4.8.1. Key country dynamic
    • 7.4.8.2. Regulatory framework
    • 7.4.8.3. Competitive insights
    • 7.4.8.4. Sweden Intravenous Solutions market estimates and forecasts, 2021 - 2033 (Revenue USD Million)
  • 7.4.9. Norway
    • 7.4.9.1. Key country dynamic
    • 7.4.9.2. Regulatory framework
    • 7.4.9.3. Competitive insights
    • 7.4.9.4. Norway Intravenous Solutions market estimates and forecasts, 2021 - 2033 (Revenue USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Asia Pacific Intravenous Solutions market estimates and forecasts, 2021 - 2033 (Revenue USD Million)
  • 7.5.2. Japan
    • 7.5.2.1. Key country dynamic
    • 7.5.2.2. Regulatory framework
    • 7.5.2.3. Competitive insights
    • 7.5.2.4. Japan Intravenous Solutions market estimates and forecasts, 2021 - 2033 (Revenue USD Million)
  • 7.5.3. China
    • 7.5.3.1. Key country dynamic
    • 7.5.3.2. Regulatory framework
    • 7.5.3.3. Competitive insights
    • 7.5.3.4. China Intravenous Solutions market estimates and forecasts, 2021 - 2033 (Revenue USD Million)
  • 7.5.4. India
    • 7.5.4.1. Key country dynamic
    • 7.5.4.2. Regulatory framework
    • 7.5.4.3. Competitive insights
    • 7.5.4.4. India Intravenous Solutions market estimates and forecasts, 2021 - 2033 (Revenue USD Million)
  • 7.5.5. South Korea
    • 7.5.5.1. Key country dynamic
    • 7.5.5.2. Regulatory framework
    • 7.5.5.3. Competitive insights
    • 7.5.5.4. South Korea Intravenous Solutions market estimates and forecasts, 2021 - 2033 (Revenue USD Million)
  • 7.5.6. Australia
    • 7.5.6.1. Key country dynamic
    • 7.5.6.2. Regulatory framework
    • 7.5.6.3. Competitive insights
    • 7.5.6.4. Australia Intravenous Solutions market estimates and forecasts, 2021 - 2033 (Revenue USD Million)
  • 7.5.7. Thailand
    • 7.5.7.1. Key country dynamic
    • 7.5.7.2. Regulatory framework
    • 7.5.7.3. Competitive insights
    • 7.5.7.4. Thailand Intravenous Solutions market estimates and forecasts, 2021 - 2033 (Revenue USD Million)
• 7.6. Latin America
  • 7.6.1. Latin America Intravenous Solutions Market Estimates and Forecasts, 2021 - 2033 (Revenue USD Million)
  • 7.6.2. Brazil
    • 7.6.2.1. Key country dynamic
    • 7.6.2.2. Regulatory framework
    • 7.6.2.3. Competitive insights
    • 7.6.2.4. Brazil Intravenous Solutions market estimates and forecasts, 2021 - 2033 (Revenue USD Million)
  • 7.6.3. Argentina
    • 7.6.3.1. Key country dynamic
    • 7.6.3.2. Regulatory framework
    • 7.6.3.3. Competitive insights
    • 7.6.3.4. Argentina Intravenous Solutions market estimates and forecasts, 2021 - 2033 (Revenue USD Million)
• 7.7. MEA
  • 7.7.1. MEA Intravenous Solutions market estimates and forecasts, 2021 - 2033 (Revenue USD Million)
  • 7.7.2. South Africa
    • 7.7.2.1. Key country dynamic
    • 7.7.2.2. Regulatory framework
    • 7.7.2.3. Competitive insights
    • 7.7.2.4. South Africa Intravenous Solutions market estimates and forecasts, 2021 - 2033 (Revenue USD Million)
  • 7.7.3. Saudi Arabia
    • 7.7.3.1. Key country dynamic
    • 7.7.3.2. Regulatory framework
    • 7.7.3.3. Competitive insights
    • 7.7.3.4. Saudi Arabia Intravenous Solutions market estimates and forecasts, 2021 - 2033 (Revenue USD Million)
  • 7.7.4. UAE
    • 7.7.4.1. Key country dynamic
    • 7.7.4.2. Regulatory framework
    • 7.7.4.3. Competitive insights
    • 7.7.4.4. UAE Intravenous Solutions market estimates and forecasts, 2021 - 2033 (Revenue USD Million)
  • 7.7.5. Kuwait
    • 7.7.5.1. Key country dynamic
    • 7.7.5.2. Regulatory framework
    • 7.7.5.3. Competitive insights
    • 7.7.5.4. Kuwait Intravenous Solutions market estimates and forecasts, 2021 - 2033 (Revenue USD Million)

Chapter 8. Competitive Landscape

• 8.1. Participant Overview
• 8.2. Company Market Position Analysis/Company Market Share Analysis, (2024)
• 8.3. Company Categorization
• 8.4. Strategy Mapping
• 8.5. Company Profiles/Listing
  • 8.5.1. Fresenius Kabi AG
    • 8.5.1.1. Overview
    • 8.5.1.2. Financial performance
    • 8.5.1.3. Product benchmarking
    • 8.5.1.4. Strategic initiatives
  • 8.5.2. B. Braun SE
    • 8.5.2.1. Overview
    • 8.5.2.2. Financial performance
    • 8.5.2.3. Product benchmarking
    • 8.5.2.4. Strategic initiatives
  • 8.5.3. Baxter
    • 8.5.3.1. Overview
    • 8.5.3.2. Financial performance
    • 8.5.3.3. Product benchmarking
    • 8.5.3.4. Strategic initiatives
  • 8.5.4. Otsuka Pharmaceutical Co., Ltd.
    • 8.5.4.1. Overview
    • 8.5.4.2. Financial performance
    • 8.5.4.3. Product benchmarking
    • 8.5.4.4. Strategic initiatives
  • 8.5.5. Pfizer, Inc.
    • 8.5.5.1. Overview
    • 8.5.5.2. Financial performance
    • 8.5.5.3. Product benchmarking
    • 8.5.5.4. Strategic initiatives
  • 8.5.6. JW Life Science
    • 8.5.6.1. Overview
    • 8.5.6.2. Financial performance
    • 8.5.6.3. Product benchmarking
    • 8.5.6.4. Strategic initiatives
  • 8.5.7. Vifor Pharma
    • 8.5.7.1. Overview
    • 8.5.7.2. Financial performance
    • 8.5.7.3. Product benchmarking
    • 8.5.7.4. Strategic initiatives
  • 8.5.8. ICU Medical, Inc.
    • 8.5.8.1. Overview
    • 8.5.8.2. Financial performance
    • 8.5.8.3. Product benchmarking
    • 8.5.8.4. Strategic initiatives